Pharmaceutical Industry Information Portal

HomeTop

Top

Bayer intends to discontinue partnership with Atara on CAR-T for $670 million

Atara Biotherapeutics, Inc., a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and...

Viatris and Biocon Biologics launch Abevmy, oncology biosimilar, in Canada

Viatris Inc. and Biocon Biologics Ltd., a subsidiary of Biocon Ltd., announced May 19th, that Abevmy® (bevacizumab) is now available in Canada. Abevmy, co-developed...

Pfizer’s $11.6 billion purchase of Biohaven could lead to new biotech deals

Pfizer's $11.6 billion deal for migraine specialist Biohaven Pharmaceutical has kindled expectations on Wall Street that it may usher in more buyouts as cash-flush...

Yale, JDRF and NexImmune, $600,000 grant for diabetes research

NexImmune, Inc., Yale and JDRF have begun a two-year project to explore the use of NexImmune’s AIM nanoparticles in combination with an anti-CD3 mAb...

AbbVie and Cerebras collaborate to accelerate artificial intelligence biopharmaceutical research

Cerebras Systems, the pioneer in high performance artificial intelligence (AI) computing, and AbbVie, a global biopharmaceutical company, announced a landmark achievement in AbbVie’s AI...

EuroAPI, split from Sanofi, rises after stock market debut

EuroAPI, Sanofi’s pharmaceutical-ingredients spinoff, rose on its first trading day in Paris, in an early sign that appetite is recovering in Europe’s dormant listings...
spot_img

Expert Articles

spot_img